DJ-1：与 HR 阳性乳腺癌预后、化疗耐药性和微环境趋化因子表达相关的潜在生物标记物

IF 3.5 3区医学 Q2 IMMUNOLOGY

Journal of Immunology Research Pub Date : 2023-12-13 DOI:10.1155/2023/5041223

Yinghong Xie, Yuancheng Li, Mengzhu Yang

{"title":"DJ-1：与 HR 阳性乳腺癌预后、化疗耐药性和微环境趋化因子表达相关的潜在生物标记物","authors":"Yinghong Xie, Yuancheng Li, Mengzhu Yang","doi":"10.1155/2023/5041223","DOIUrl":null,"url":null,"abstract":"DJ-1 is significantly elevated in various malignancies. However, the clinical significance of DJ-1 in hormone receptor (HR)-positive (HR+) breast cancer remains unclear. We evaluated DJ-1 expression in different databases and validated in vitro assay by RT-PCR and western blot among HR+ breast cancer. The correlations between DJ-1 level and tumor-immune were calculated. Mutational landscape, enriched signaling pathways, and drug sensitivity analyses were also assessed between DJ-1 high and low-expression groups. DJ-1 was upregulated in HR+ breast cancer, and high DJ-1 expression was significantly linked with poor prognosis. DJ-1 was correlated with the expression and function of different immune cells. The low DJ-1 group showed sensitivity to paclitaxel and docetaxel, while the high-expression group showed sensitivity to doxorubicin. CTLA4 and PD-L1 were more sensitive in high-DJ-1 group. It is involved in a range of pathways and might behave as a novel biomarker of prognostic value for the immune environment and drug sensitivity in HR+ breast cancer.","PeriodicalId":15952,"journal":{"name":"Journal of Immunology Research","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"DJ-1: A Potential Biomarker Related to Prognosis, Chemoresistance, and Expression of Microenvironmental Chemokine in HR-Positive Breast Cancer\",\"authors\":\"Yinghong Xie, Yuancheng Li, Mengzhu Yang\",\"doi\":\"10.1155/2023/5041223\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"DJ-1 is significantly elevated in various malignancies. However, the clinical significance of DJ-1 in hormone receptor (HR)-positive (HR+) breast cancer remains unclear. We evaluated DJ-1 expression in different databases and validated in vitro assay by RT-PCR and western blot among HR+ breast cancer. The correlations between DJ-1 level and tumor-immune were calculated. Mutational landscape, enriched signaling pathways, and drug sensitivity analyses were also assessed between DJ-1 high and low-expression groups. DJ-1 was upregulated in HR+ breast cancer, and high DJ-1 expression was significantly linked with poor prognosis. DJ-1 was correlated with the expression and function of different immune cells. The low DJ-1 group showed sensitivity to paclitaxel and docetaxel, while the high-expression group showed sensitivity to doxorubicin. CTLA4 and PD-L1 were more sensitive in high-DJ-1 group. It is involved in a range of pathways and might behave as a novel biomarker of prognostic value for the immune environment and drug sensitivity in HR+ breast cancer.\",\"PeriodicalId\":15952,\"journal\":{\"name\":\"Journal of Immunology Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2023-12-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Immunology Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2023/5041223\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Immunology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/5041223","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在各种恶性肿瘤中，DJ-1 都会明显升高。然而，DJ-1在激素受体（HR）阳性（HR+）乳腺癌中的临床意义仍不清楚。我们评估了不同数据库中DJ-1的表达，并通过RT-PCR和Western blot对HR+乳腺癌的体外检测进行了验证。计算了DJ-1水平与肿瘤免疫之间的相关性。还评估了DJ-1高表达组和低表达组之间的突变情况、富集信号通路和药物敏感性分析。DJ-1在HR+乳腺癌中上调，DJ-1高表达与预后不良显著相关。DJ-1与不同免疫细胞的表达和功能相关。低DJ-1组对紫杉醇和多西他赛敏感，而高表达组对多柔比星敏感。高DJ-1组对CTLA4和PD-L1更敏感。DJ-1参与了一系列通路，可能会成为对HR+乳腺癌的免疫环境和药物敏感性有预后价值的新型生物标记物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

DJ-1: A Potential Biomarker Related to Prognosis, Chemoresistance, and Expression of Microenvironmental Chemokine in HR-Positive Breast Cancer

DJ-1 is significantly elevated in various malignancies. However, the clinical significance of DJ-1 in hormone receptor (HR)-positive (HR+) breast cancer remains unclear. We evaluated DJ-1 expression in different databases and validated in vitro assay by RT-PCR and western blot among HR+ breast cancer. The correlations between DJ-1 level and tumor-immune were calculated. Mutational landscape, enriched signaling pathways, and drug sensitivity analyses were also assessed between DJ-1 high and low-expression groups. DJ-1 was upregulated in HR+ breast cancer, and high DJ-1 expression was significantly linked with poor prognosis. DJ-1 was correlated with the expression and function of different immune cells. The low DJ-1 group showed sensitivity to paclitaxel and docetaxel, while the high-expression group showed sensitivity to doxorubicin. CTLA4 and PD-L1 were more sensitive in high-DJ-1 group. It is involved in a range of pathways and might behave as a novel biomarker of prognostic value for the immune environment and drug sensitivity in HR+ breast cancer.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Immunology Research IMMUNOLOGY-

CiteScore

6.90

自引率

2.40%

发文量

423

审稿时长

15 weeks

期刊介绍： Journal of Immunology Research is a peer-reviewed, Open Access journal that provides a platform for scientists and clinicians working in different areas of immunology and therapy. The journal publishes research articles, review articles, as well as clinical studies related to classical immunology, molecular immunology, clinical immunology, cancer immunology, transplantation immunology, immune pathology, immunodeficiency, autoimmune diseases, immune disorders, and immunotherapy.